JOHN HARMON, M.D.
Radiology at Eastern Ave, Baltimore, MD

2012011, May 10, 2012

Jul 15, 2010

13/383612

Aaron T Tabor - Winston-salem NC, US
John Harmon - Baltimore MD, US

A61K 48/00, A61P 17/00, A61M 37/00, C12N 15/63

514 44 R, 435455, 604 22, 604 20

Disclosed are methods and compositions to genetically modify substantially intact cells having cosmetic function to enhance the cosmetic appearance in mammals so as to enhance and/or maintain a biochemical and/or physiological process that has a positive effect on cosmetic appearance. The methods and compositions may provide cosmetic benefits such as reduced skin sagging, increased skin thickness, reduced wrinkles, increased skin thickness and collagen content, increased skin tone and elastic-ity, increased skin hydration, and improved skin texture and color.

2009018, Jul 23, 2009

Jan 2, 2009

12/348164

Aaron Thomas Tabor - Winston-Salem NC, US
John Watson Harmon - Baltimore MD, US

A61K 38/02, C12N 5/06, C12N 15/87, C12N 15/88, A61K 31/7088

514 2, 435375, 435455, 435458, 435461, 435459, 514 44

Disclosed are methods and compositions to genetically modify substantially intact cells having cosmetic function to enhance the cosmetic appearance in mammals so as to enhance and/or maintain a biochemical and/or physiological process that has a positive effect on cosmetic appearance. The methods and compositions may provide cosmetic benefits such as reduced skin sagging, increased skin thickness, reduced wrinkles, increased skin thickness and collagen content, increased skin tone and elasticity, increased skin hydration, and improved skin texture and color.

2009003, Jan 29, 2009

Feb 6, 2006

11/883554

John W. Harmon - Baltimore MD, US
Guy Pierre Marti - Cockeysville MD, US
Mark John Ferguson - Inverurie, GB

The Johns Hopkins University - Baltimore MD

A61N 1/30

604 21, 604 20

A cartridge for administration of a bioactive agent may include a plurality of chambers, including at least a first chamber and a second chamber. Each of the chambers may contain a component of a composition to be administered to a tissue site of a subject. For example, the first chamber may contain the bioactive agent and the second chamber may contain a liquid for suspending the bioactive agent prior to administration to the tissue site. An apparatus for administering or delivering a bioactive agent may include the cartridge and may further include an energy source for providing an electrical pulse to the tissue site. The apparatus may further cause mixing of the bioactive agent with the liquid in the cartridge. For example, the apparatus may impact the cartridge to result in mixing of the bioactive agent with the liquid. A method for combining a bioactive agent with a liquid forms a composition for delivering to a tissue site.

2009031, Dec 17, 2009

May 22, 2007

12/300685

John W. Harmon - Baltimore MD, US
Guy Pierre Marti - Cockeysville MD, US
Tomoharu Miyashita - Baltimore MD, US
Michael Gibson - Baltimore MD, US
Todd Armstrong - Elkridge MD, US
Pramod Bonde - Abingdon MD, US

THE JOHN HOPKINS UNIVERSITY - BALTIMORE MD

A61K 48/00, A61P 35/00, A61K 35/00, A61K 35/12

424 9321

Enhancing the immune response to esophageal tumor cells reduces the incidence of esophageal cancer developing, recurring, or metastasizing. Esophageal cancer cells are modified to render them more immunogenic and proliferation compromised. They are used in an antigenic preparation to raise a T cell response in the recipient.